The Journal of Pharmacogenomics & Pharmacoproteomics publishes articles on new innovations in the field of personalized medicines. The original research articles or current reviews published under the journal deals with the influence of genetic variations on drug response in patients and viceversa. The journal aims to publish innovations in customized drug discovery using proteome technology. The journal provides an open access platform to publish latest advancements in the field of drug design, drug development and drug delivery. Journal of Pharmacogenomics & Pharmacoproteomics is an open access, peer reviewed journal that covers a wide range of topics in its discipline to give authors a place to contribute their valuable work to the journal. The peer review process ensures that only important, high-quality articles are published for readers and authors in the scholarly, academic, and scientific fields. An internationally renowned Editorial Board provides competent support for the Pharmacogenomics & Pharmacoproteomics Peer Reviewed Journal. The impact factor for the Pharmacogenomics & Pharmacoproteomics journal is primarily determined by the number of articles that go through a single blind peer review process by an expert Editorial Board in order to ensure excellence, the core of the work, and the number of citations received for the same published articles. Every article published by the open access journals for pharmacogenomics and pharmacoproteomics is immediately available to everyone for free, including the full text and abstracts. A biological mechanism called RNA interference (RNAi), commonly referred to as gene silencing, disrupts the expression of particular genes in conditions like cancer. It can be applied to enhance the precision, effectiveness, and stability of therapies, particularly gene therapy. The distribution of oligonucleotide medications to difficult-to-reach areas of the body and the prevalence of harmful side effects are two problems, though. The study covered the use of RNA interference (RNAi) in the management of COVID 19, a novel coronavirus disease that affects numerous nations. By defining the processes and uses of RNAi, identifying a number of cancer transmission networks, and offering therapeutic information for their development, this study intends to analyse the existing difficulties of RNAi therapy. It is important to note that exosomes and lipid-based delivery methods have revolutionised RNAi therapy by lowering immunogenicity and increasing cell affinity. New information on RNAi drug development may emerge from a clearer comprehension of the mechanics and difficulties associated with RNAi in the treatment of cancer. One of the most fatal illnesses, cancer has a terrible prognosis and few effective treatments. In general, cancer can affect any region of the body and typically starts in the epithelium. While cancer mortality has decreased since 1990, according to the most recent statistics on the disease larger populations still have a higher proportion of patients who lack access to more effective and painless therapies. The treatments for cancer have included conventional surgery, radiation therapy, and chemotherapy. The long-term financial, physical, and psychological costs of these methods are however substantial. Thus, the need for fresh approaches to enhance treatment outcomes and lessen these burdens is important. Small interfering RNAs (siRNAs) and MicroRNAs (miRNAs) are used in RNAi to immediately influence cellular events rather than turning them into proteins.